John T. McDevitt serves as the Chair for the Department Biomaterials and Biomimetics at New York University College of Dentistry and is a pioneer in the development of ‘programmable bio-nano-chip’ technologies. He has a strong track record of translating essential bioscience discoveries into real-world clinical practice. In this capacity he serves as the Scientific Founder for several companies in areas related to medical microdevice technologies. His most recent company, SensoDx, features a universal platform sensor technology with capacity to digitize biological signatures for a broad range of key health conditions. McDevitt and his team over the past decade have raised over $25M in Federal and Foundation support. His recent research has been sponsored by major programs funded by the National Institute of Dental and Craniofacial Research (NIDCR) division of the National Institutes of Health (NIH), the Bill and Melinda Gates Foundation, Cancer Prevention Research Institute of Texas (CPRIT), the National Aeronautics and Space Administration (NASA) and the United Kingdom’s Home Office Scientific Development Branch.
McDevitt and his team have written more than 185 peer-reviewed scientific manuscripts and have contributed to more than 100 patents and patent applications. This work was recognized with the “Best of What’s New Award” in the Medical Device Category for 2008 by Popular Science as well as for the “Best Scientific Advances Award” in 1998 by the Science Coalition. Dr. McDevitt’s individual honors include the Presidential Young Investigator Award, the 2010 California Polytechnic Distinguished Alumni Award and the Exxon Education Award. Over the past 5 years Dr. McDevitt has served as the Principal Investigator for 6 major clinical trials and 2 clinical pilot studies, all involving the programmable bio-nano-chip. Through these clinical efforts, mini-sensor ensembles are being developed for major diseases in the areas of oral cancer, cardiac heart disease, trauma, drugs of abuse, ovarian cancer and prostate cancer.